IQWiG assessment: linvoseltamab for relapsed or refractory multiple myeloma – unmet evidence need

Linvoseltamab is another bispecific antibody now available, but the results of a comparative study are not expected until 2026. Numerous drugs are available for the treatment of multiple myeloma. What is lacking is comparative evidence – so there is more of an unmet evidence need than an unmet medical need. Linvoseltamab is used as monotherapy for the treatment of adults with relapsed or refractory multiple myeloma who have already undergone at least three lines of treatment. In April 2025, the European Commission granted a conditional marketing authorization for this bispecific antibody. This meant that the drug was available at an early stage, even though sufficient data was not yet available to support a full marketing authorization.